https://www.selleckchem.com/products/AZD0530.html
However, only one monoclonal antibody candidate has been evaluated in a phase I clinical trial. At this moment, it is essential to evaluate the safety and efficacy of potential candidates in clinical trials to validate the importance of this platform drug-vaccine conjugation in order to manage or overcome METH addiction. Significant improvements have been developed for immunopharmacotherapies for METH addiction over the last two decades. However, only one monoclonal antibody candidate has been evaluated in a phase I clinical trial. At t
Like
Comment
Share
